September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Optical Coherence Tomography Minimum Intensity as an objective measure for the detection of hydroxychloroquine toxicity.
Author Affiliations & Notes
  • Ali M Allahdina
    National Eye Institute, NIH, Bethesda, Maryland, United States
  • Paul F Stetson
    Research and Development, Carl Zeiss Meditec, Dublin, California, United States
  • Wai T Wong
    National Eye Institute, NIH, Bethesda, Maryland, United States
  • Emily Y Chew
    National Eye Institute, NIH, Bethesda, Maryland, United States
  • Catherine A Cukras
    National Eye Institute, NIH, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Ali Allahdina, None; Paul Stetson, Carl Zeiss Meditec (E), Carl Zeiss Meditec (P); Wai Wong, None; Emily Chew, None; Catherine Cukras, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3408. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ali M Allahdina, Paul F Stetson, Wai T Wong, Emily Y Chew, Catherine A Cukras; Optical Coherence Tomography Minimum Intensity as an objective measure for the detection of hydroxychloroquine toxicity.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3408.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Spectral domain Optical Coherence Tomography (SD-OCT) has been previously shown to be a useful modality in the detection of hydroxychloroquine toxicity both for qualitative inspection and quantitative ananlysis. OCT Minimum Intensity (MI) provides a different analysis of the OCT data to visualize photoreceptor disruption. We compare OCT MI analysis to multifocal electroretinography (mfERG) reference testing in participants with and without toxicity.

Methods : Fifty-seven study participants (91.2% female; mean age, 55.7±10.4 years; mean duration of hydroxychloroquine treatment, 15.0±7.5 years) were divided into toxicity affected (n=19) and unaffected (n=38) groups using objective mfERG criteria. A Cirrus-HD system was used to obtain macular 512x128 cube scans and were analyzed using the OCT MI algorithm, a novel quantitative technique developed by Carl Zeiss Meditec, Inc. (Dublin, CA). The OCT MI results were analyzed in each ETDRS subfield and data for one eye of each participant was used in a t-test analysis comparing the affected and unaffected groups. A receiver operating characteristic (ROC) curve was plotted and area under the curve (AUC) was calculated for each subfield to assess the sensitivity and specificity of the OCT MI to discriminate between presence and absence of HCQ retinal toxicity.

Results : The mean of the median OCT MI values measured in all 9 ETDRS subfields were significantly higher in the affected group compared with those of the unaffected group (median difference in MI > 3.50, P < 0.005 for all comparisons). The subfields with the greatest difference in the median OCT MI values between affected and unaffected patients were the Inner Inferior subfields (median difference MI >10.00; P<0.0001). ROC analysis of Inner Inferior subfields showed high sensitivity and high specificity (AUC= 0.997; Sensitivity=100%, Specificity= 89.5%, with MI cutoff= 54.3).

Conclusions : Analysis of the OCT MI, especially in the Inner Inferior subfield, is an objective anatomical measure that appears to demonstrate clinically useful sensitivity and specificity for the detection of hydroxychloroquine toxicity as identified by mfERG. OCT is a widely accessible imaging modality and incorporating OCT MI analysis to patient evaluation may aid in the detection of hydroxychloroquine-induced retinal toxicity.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×